Real-world analysis of teclistamab in 123 RRMM patients from Germany
Sign Up to like & getrecommendations! Published in 2024 at "Leukemia"
DOI: 10.1038/s41375-024-02154-5
Abstract: Teclistamab, a B-cell maturation antigen (BCMA) × CD3 directed bispecific antibody, has shown high response rates and durable remissions in the MAJESTEC-1 trial in patients with relapsed and refractory multiple myeloma (RRMM). We retrospectively assessed efficacy and… read more here.
Keywords: ide cel; rrmm; world analysis; real world ... See more keywords
Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER Study
Sign Up to like & getrecommendations! Published in 2024 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2024.2352856
Abstract: Abstract Objective To understand clinicians’ current teclistamab step-up dosing (SUD) model and how they envision future administration models, as well as perceived barriers and facilitators to these models in day-to-day clinical practice. Methods Interviews of… read more here.
Keywords: oncology; step dosing; multiple myeloma; treatment ... See more keywords
Abstract B104: Comparative Efficacy of Pomalidomide vs. Teclistamab in Preventing AL Amyloidosis Progression in Refractory Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Immunology Research"
DOI: 10.1158/2326-6074.io2025-b104
Abstract: Background: AL amyloidosis progression is a critical complication in patients with refractory multiple myeloma (MM), leading to poor outcomes. Pomalidomide, an immunomodulatory drug, and Teclistamab, a bispecific antibody targeting BCMA, are both used in the… read more here.
Keywords: multiple myeloma; amyloidosis progression; progression; teclistamab ... See more keywords
Cytomegalovirus Reactivation in Patients with Multiple Myeloma Treated with Teclistamab: Risk Factors and Clinical Impact
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-201519
Abstract: Introduction: Teclistamab is a bispecific B-cell maturation antigen (BCMA)-CD3 directed T-cell antibody recently FDA approved for treatment of relapsed or refractory multiple myeloma (RRMM). Viral infections have been reported as a common complication of teclistimab.… read more here.
Keywords: cmv reactivation; cmv; risk; teclistamab ... See more keywords
Real-World Characteristics, Step-up Dosing Patterns, and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab at Texas Oncology Community-Based Treatment Centers
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-210497
Abstract: Background Teclistamab was the first B-cell maturation antigen (BCMA) x CD3 bispecific antibody to gain US regulatory approval for relapsed/refractory multiple myeloma (MM) on 10/25/22. While teclistamab step-up dosing (SUD) was predominantly administered in inpatient… read more here.
Keywords: oncology; treatment; teclistamab; pts received ... See more keywords
Health care resource utilization in patients with multiple myeloma receiving bispecific antibody therapy with teclistamab: A Medicare claims database analysis in the US
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3975
Abstract: Background: Four bispecific antibodies (bsAbs), teclistamab, elranatamab, talquetamab, and linvoseltamab have been approved for use in the U.S. in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). The objective of this analysis was to describe… read more here.
Keywords: teclistamab setting; treatment; teclistamab; index date ... See more keywords
Tracking peripheral residual disease in myeloma: Clonotypic sequencing and mass spectrometry in the teclistamab era
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3998
Abstract: Multiple myeloma (MM) is an incurable hematological cancer and is characterized by the proliferation of a plasma cell clone secreting a monoclonal protein. Teclistamab, a BCMA-directed bispecific antibody, has demonstrated improved outcomes in relapsed and… read more here.
Keywords: disease; mass spectrometry; teclistamab; mass ... See more keywords
Teclisito: Low-intensity teclistamab in the outpatient setting for Relapsed/Refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-4063
Abstract: Bispecific antibodies targeting BCMA have transformed MM management, albeit access in low- and middle-income countries (LMICs) remains limited due to economic and infrastructural barriers. The MajesTEC-1 trial established the efficacy of teclistamab, an anti-BCMA/CD3 bispecific… read more here.
Keywords: refractory; teclistamab; response; outpatient ... See more keywords
Bridging the rural gap: Real-world teclistamab outcomes from the u.S. midwest myeloma network
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-4597
Abstract: Background: Teclistamab, a BCMA×CD3 bispecific T-cell engager, offers an off-the-shelf immunotherapy option for relapsed/refractory multiple myeloma (RRMM). Despite pivotal trial efficacy, real-world outcomes in elderly, comorbid, and geographically isolated patients—underrepresented in MajesTEC-1—are poorly characterized. The… read more here.
Keywords: median ttp; progression; real world; teclistamab ... See more keywords
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-4599
Abstract: Background: Teclistamab, a bispecific T-cell engager targeting BCMA, has demonstrated significant efficacy in relapsed/refractory multiple myeloma (MM) but is associated with profound immunosuppression. Cytomegalovirus (CMV) reactivation represents a potentially serious infectious complication, yet comprehensive data… read more here.
Keywords: treatment; cmv reactivation; teclistamab; reactivation ... See more keywords
Real-world outcomes of teclistamab in triple-exposed relapsed/refractory multiple myeloma: Brazilian single-center experience
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7607
Abstract: Background: Teclistamab is a B-cell maturation antigen (BCMA)-targeting bispecific T-cell engager approved for commercialization in Brazil in July 2023 for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least a proteasome inhibitor (PI),… read more here.
Keywords: triple exposed; multiple myeloma; real world; teclistamab ... See more keywords